Gilead's CEO Gives Glimpse Of Strategic Opportunities As HCV Sales Slide Continues
Gilead CEO John Milligan, pressured by an analyst, gave a brief rundown of the company's strategic priorities as investors wait for the company to spend its $34bn in cash on revenue-increasing opportunities to offset declining hepatitis C drug sales.
You may also be interested in...
ViiV and Merck are looking to novel mechanisms of action as an opportunity to make up ground on HIV leader Gilead, which has de-emphasized early virology research.
Gilead's Kite acquisition may finally have appeased investors' thirst for a major deal with a transaction that will diversify revenue and expand its oncology portfolio.
Gilead thinks 2017 HCV sales could reach as high as $9bn, still down from 2016, but higher than projected six months ago. Meanwhile, sales of TAF-based HIV regimens continue to grow and gain market share.